GOVX
GeoVax Labs, Inc.
Price Chart
No historical data available
Latest Quote
$0.72
+0.00 (+0.56%)
Current Price
| Previous Close | $0.72 |
| Open | $0.70 |
| Day High | $0.73 |
| Day Low | $0.68 |
| Volume | 704,231 |
Stock Information
| Shares Outstanding | 5.21M |
| Total Debt | $323K |
| Cash Equivalents | $3.14M |
| Net Income | $-20.43M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.76M |
| EPS (TTM) | $-5.62 |
| Exchange | NCM |
Recent Price History
No history data available. Data will be fetched automatically.
About GeoVax Labs, Inc.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
đ° Latest News
GeoVax targets Q4 phase 3 trial for MVA mpox vaccine with EMA expedited pathway
Proactive âĸ 2026-08-10T21:02:30Z
GeoVax Labs (GOVX) Stock Fair Value Moves Lower After Pipeline Shift
Simply Wall St. âĸ 2026-06-27T14:07:21Z
GeoVax Labs (GOVX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Zacks âĸ 2026-06-12T13:55:02Z
Is Co-Diagnostics National Securityâs Next Diagnostic Pick?
MarketBeat âĸ 2026-05-28T15:00:00Z
Why Is GOVX Stock Falling Today?
Stocktwits âĸ 2026-05-26T15:45:19Z
How The GeoVax Labs (GOVX) Story Is Shifting With Vaccine Progress And Funding Risks
Simply Wall St. âĸ 2026-05-26T11:08:30Z
All You Need to Know About GeoVax Labs (GOVX) Rating Upgrade to Buy
Zacks âĸ 2026-05-15T16:00:02Z
How The GeoVax Labs (GOVX) Story Is Shifting After The Rating Downgrade And Valuation Reset
Simply Wall St. âĸ 2026-04-14T13:05:52Z
Why The GeoVax Labs (GOVX) Story Is Shifting As Valuation Holds And Risks Rise
Simply Wall St. âĸ 2026-03-31T07:05:39Z
How The Story On GeoVax Labs (GOVX) Is Shifting Toward Execution Risk And Funding Constraints
Simply Wall St. âĸ 2026-03-11T17:09:41Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $2,489,145 | $3,954,576 | $0 | $81,526 |
| Operating Revenue | $2,489,145 | $3,954,576 | $0 | $81,526 |
| Expenses | ||||
| Interest Expense | $0 | $21,375 | $0 | $0 |
| Total Expenses | $24,128,192 | $29,098,856 | $26,742,939 | $14,110,090 |
| Net Non Operating Interest Income Expense | $174,276 | $151,984 | $776,177 | $7,439 |
| Interest Expense Non Operating | $0 | $21,375 | $0 | $0 |
| Operating Expense | $24,128,192 | $29,098,856 | $26,742,939 | $14,110,090 |
| General And Administrative Expense | $6,006,673 | $5,385,254 | $6,022,173 | $4,986,611 |
| Other Income Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-21,464,771 | $-24,992,296 | $-25,966,762 | $-14,021,125 |
| Net Interest Income | $174,276 | $151,984 | $776,177 | $7,439 |
| Interest Income | $174,276 | $173,359 | $776,177 | $7,439 |
| Normalized Income | $-21,464,771 | $-24,992,296 | $-25,966,762 | $-14,021,125 |
| Net Income From Continuing And Discontinued Operation | $-21,464,771 | $-24,992,296 | $-25,966,762 | $-14,021,125 |
| Total Operating Income As Reported | $-21,639,047 | $-25,144,280 | $-26,742,939 | $-14,028,564 |
| Net Income Common Stockholders | $-21,464,771 | $-24,992,296 | $-25,966,762 | $-14,021,125 |
| Net Income | $-21,464,771 | $-24,992,296 | $-25,966,762 | $-14,021,125 |
| Net Income Including Noncontrolling Interests | $-21,464,771 | $-24,992,296 | $-25,966,762 | $-14,021,125 |
| Net Income Continuous Operations | $-21,464,771 | $-24,992,296 | $-25,966,762 | $-14,021,125 |
| Pretax Income | $-21,464,771 | $-24,992,296 | $-25,966,762 | $-14,021,125 |
| Interest Income Non Operating | $174,276 | $173,359 | $776,177 | $7,439 |
| Operating Income | $-21,639,047 | $-25,144,280 | $-26,742,939 | $-14,028,564 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-22.40 | $-120.46 | $-357.25 | $-311.25 |
| Basic EPS | $-22.40 | $-120.46 | $-357.25 | $-311.25 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-21,396,015 | $-24,875,553 | $-25,892,593 | $-13,972,280 |
| Reconciled Depreciation | $68,756 | $95,368 | $74,169 | $56,284 |
| EBITDA (Bullshit earnings) | $-21,396,015 | $-24,875,553 | $-25,892,593 | $-13,972,280 |
| EBIT | $-21,464,771 | $-24,970,921 | $-25,966,762 | $-14,028,564 |
| Diluted Average Shares | $958,443 | $207,482 | $72,691 | $45,261 |
| Basic Average Shares | $958,443 | $207,482 | $72,691 | $45,261 |
| Diluted NI Availto Com Stockholders | $-21,464,771 | $-24,992,296 | $-25,966,762 | $-14,021,125 |
| Research And Development | $18,121,519 | $23,713,602 | $20,720,766 | $9,123,479 |
| Selling General And Administration | $6,006,673 | $5,385,254 | $6,022,173 | $4,986,611 |
| Other Gand A | $6,006,673 | $5,385,254 | $6,022,173 | $4,986,611 |
| Total Unusual Items | - | - | - | $0 |
| Total Unusual Items Excluding Goodwill | - | - | - | $0 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-08-29
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $3,775,132 | $4,988,535 | $5,693,338 | $26,600,034 |
| Total Assets | $6,341,868 | $8,155,867 | $9,283,219 | $31,347,928 |
| Total Non Current Assets | $1,027,217 | $220,984 | $1,397,477 | $2,409,198 |
| Non Current Prepaid Assets | $36,947 | $11,010 | $1,117,788 | $2,174,286 |
| Goodwill And Other Intangible Assets | $50,000 | $60,000 | $70,000 | $80,000 |
| Other Intangible Assets | $50,000 | $60,000 | $70,000 | $80,000 |
| Current Assets | $5,314,651 | $7,934,883 | $7,885,742 | $28,938,730 |
| Other Current Assets | $66,843 | $10,000 | - | - |
| Prepaid Assets | $2,162,067 | $1,758,533 | $1,433,153 | $1,325,998 |
| Receivables | $0 | $659,409 | $0 | $0 |
| Cash Cash Equivalents And Short Term Investments | $3,085,741 | $5,506,941 | $6,452,589 | $27,612,732 |
| Cash And Cash Equivalents | $3,085,741 | $5,506,941 | $6,452,589 | $27,612,732 |
| Other Receivables | - | $659,409 | - | - |
| Other Non Current Assets | - | - | $1,187,788 | $2,174,286 |
| Debt | ||||
| Total Debt | $843,170 | $0 | - | - |
| Long Term Debt And Capital Lease Obligation | $580,035 | $0 | - | - |
| Current Debt And Capital Lease Obligation | $263,135 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,516,736 | $3,107,332 | $3,519,881 | $4,747,894 |
| Total Non Current Liabilities Net Minority Interest | $580,035 | $0 | $0 | $0 |
| Current Liabilities | $1,936,701 | $3,107,332 | $3,519,881 | $4,747,894 |
| Payables And Accrued Expenses | $1,673,566 | $3,107,332 | $3,519,881 | $4,747,894 |
| Payables | $790,750 | $1,849,760 | $2,802,950 | $1,747,682 |
| Accounts Payable | $790,750 | $1,849,760 | $2,802,950 | $1,747,682 |
| Other Non Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $3,825,132 | $5,048,535 | $5,763,338 | $26,600,034 |
| Total Equity Gross Minority Interest | $3,825,132 | $5,048,535 | $5,763,338 | $26,600,034 |
| Stockholders Equity | $3,825,132 | $5,048,535 | $5,763,338 | $26,600,034 |
| Retained Earnings | $-150,820,852 | $-129,356,081 | $-104,363,785 | $-78,397,023 |
| Other | ||||
| Ordinary Shares Number | $1,732,147 | $421,475 | $79,086 | $70,226 |
| Share Issued | $1,732,147 | $421,475 | $79,086 | $70,226 |
| Tangible Book Value | $3,775,132 | $4,988,535 | $5,693,338 | $26,600,034 |
| Invested Capital | $3,825,132 | $5,048,535 | $5,763,338 | $26,600,034 |
| Working Capital | $3,377,950 | $4,827,551 | $4,365,861 | $24,190,836 |
| Capital Lease Obligations | $843,170 | $0 | - | - |
| Total Capitalization | $3,825,132 | $5,048,535 | $5,763,338 | $26,600,034 |
| Additional Paid In Capital | $154,644,252 | $134,404,195 | $110,125,146 | $104,995,301 |
| Capital Stock | $1,732 | $421 | $1,977 | $1,756 |
| Common Stock | $1,732 | $421 | $1,977 | $1,756 |
| Long Term Capital Lease Obligation | $580,035 | $0 | - | - |
| Current Capital Lease Obligation | $263,135 | $0 | - | - |
| Current Accrued Expenses | $882,816 | $1,257,572 | $716,931 | $3,000,212 |
| Net PPE | $940,270 | $149,974 | $209,689 | $234,912 |
| Accumulated Depreciation | $-403,607 | $-761,042 | $-680,674 | $-606,505 |
| Gross PPE | $1,343,877 | $911,016 | $890,363 | $841,417 |
| Leases | $0 | $115,605 | $115,605 | $115,605 |
| Machinery Furniture Equipment | $512,437 | $795,411 | $774,758 | $725,812 |
| Buildings And Improvements | $831,440 | $0 | - | - |
| Properties | $0 | $0 | $0 | $0 |
| Treasury Shares Number | - | - | $0 | - |
| Preferred Stock | - | - | - | - |
| Non Current Accrued Expenses | - | - | - | - |
Fetched: 2026-08-29
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-21,501,581 | $-24,696,164 | $-25,222,585 | $-19,164,466 |
| Operating Activities | ||||
| Operating Cash Flow | $-21,473,969 | $-24,675,511 | $-25,173,639 | $-19,030,208 |
| Cash Flow From Continuing Operating Activities | $-21,473,969 | $-24,675,511 | $-25,173,639 | $-19,030,208 |
| Operating Gains Losses | - | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-27,612 | $-20,653 | $-48,946 | $-134,258 |
| Investing Cash Flow | $-27,612 | $-20,653 | $-48,946 | $-134,258 |
| Cash Flow From Continuing Investing Activities | $-27,612 | $-20,653 | $-48,946 | $-134,258 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $18,924,172 | $21,398,383 | $0 | $27,727,194 |
| Financing Cash Flow | $19,080,381 | $23,750,516 | $4,062,442 | $35,353,328 |
| Cash Flow From Continuing Financing Activities | $19,080,381 | $23,750,516 | $4,062,442 | $35,353,328 |
| Net Common Stock Issuance | $18,924,172 | $21,398,383 | $0 | $27,727,194 |
| Common Stock Issuance | $18,924,172 | $21,398,383 | $0 | $27,727,194 |
| Repurchase Of Capital Stock | - | - | - | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $0 | $-150,000 | $0 | $0 |
| Issuance Of Debt | $0 | $135,000 | $0 | - |
| End Cash Position | $3,085,741 | $5,506,941 | $6,452,589 | $27,612,732 |
| Beginning Cash Position | $5,506,941 | $6,452,589 | $27,612,732 | $11,423,870 |
| Changes In Cash | $-2,421,200 | $-945,648 | $-21,160,143 | $16,188,862 |
| Proceeds From Stock Option Exercised | $156,209 | $2,367,133 | $4,062,442 | $7,626,134 |
| Net Issuance Payments Of Debt | $0 | $-15,000 | $0 | $0 |
| Net Short Term Debt Issuance | $0 | $-15,000 | $0 | $0 |
| Short Term Debt Payments | $0 | $-150,000 | $0 | $0 |
| Short Term Debt Issuance | $0 | $135,000 | $0 | - |
| Net PPE Purchase And Sale | $-27,612 | $-20,653 | $-48,946 | $-134,258 |
| Purchase Of PPE | $-27,612 | $-20,653 | $-48,946 | $-134,258 |
| Change In Working Capital | $-1,193,108 | $-307,227 | $-356,003 | $-5,967,441 |
| Change In Other Current Assets | $27,623 | $1,116,778 | $986,498 | $-2,163,276 |
| Change In Payables And Accrued Expense | $-1,465,596 | $-412,549 | $-1,228,013 | $-2,687,466 |
| Change In Prepaid Assets | $-414,544 | $-352,047 | $-114,488 | $-1,165,705 |
| Change In Receivables | $659,409 | $-659,409 | $0 | $49,006 |
| Stock Based Compensation | $1,115,154 | $528,644 | $1,074,957 | $902,074 |
| Depreciation Amortization Depletion | $68,756 | $95,368 | $74,169 | $56,284 |
| Depreciation And Amortization | $68,756 | $95,368 | $74,169 | $56,284 |
| Depreciation | $68,756 | - | $74,169 | $56,284 |
| Net Income From Continuing Operations | $-21,464,771 | $-24,992,296 | $-25,966,762 | $-14,021,125 |
| Preferred Stock Payments | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Change In Other Working Capital | - | - | - | $-2,163,276 |
| Long Term Debt Issuance | - | - | - | - |
| Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-08-29